Chemomab Therapeutics Ltd. (CMMB) NASDAQ
$0.67 0.01 (1.53%)
Market Cap: $1.21M
As of 04/23/24 04:00 PM EDT. Market closed.
Chemomab Therapeutics Ltd. (CMMB)
NASDAQ
$0.67
0.01 (1.53%)
Market Cap: $1.21M
As of 04/23/24 04:00 PM EDT. Market closed.
Add to Portfolio
chemomab ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. chemomab is making great strides with its novel cm-101 proprietary platform, which hinders the fundamental function of the soluble chemokine ccl24 as a regulator of major inflammatory and fibrotic pathways in multiple ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Full Time Employees
21
URL
Address
.
PRICE CHART FOR CHEMOMAB THERAPEUTICS LTD
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$0.66
Previous Close
$0.66
Days Range
$0.62 - $0.67
52 week range
$0.42 - $1.89
Volume
7,157
Avg. Volume (30 days)
34,366
Market Cap
$1.21M
Dividend Yield
-
P/E
-
Shares Outstanding
1,839,633
Open
$0.66
Previous Close
$0.66
Days Range
$0.62 - $0.67
52 week range
$0.42 - $1.89
Volume
7,157
Avg. Volume (30 days)
34,366
Market Cap
$1.21M
Dividend Yield
-
P/E
-
Shares Outstanding
1,839,633
FINANCIAL STATEMENTS FOR CHEMOMAB THERAPEUTICS LTD
LOADING...
INSIDER TRANSACTIONS FOR CHEMOMAB THERAPEUTICS LTD
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
OrbiMed Israel GP Ltd. | 10% Owner | Jan 03, 2023 | Sale | $3.58 | 336,900 | 1,207,759 | 2,311,798 | Jan 05, 2023, 04:49 PM |
Mor George Adi | Chief Scientific Officer | Jan 03, 2023 | Sale | $5.03 | 6,100 | 30,663 | 251,147 | Jan 05, 2023, 04:01 PM |
Mor George Adi | Chief Scientific Officer | Jan 03, 2023 | Sale | $5.03 | 7,700 | 38,706 | 317,075 | Jan 05, 2023, 04:01 PM |
Cohen Neil Harris | Director | Nov 16, 2022 | Sale | $2.00 | 2,409 | 4,818 | 10,000 | Nov 18, 2022, 07:53 AM |
Mor George Adi | Chief Scientific Officer | Nov 16, 2022 | Sale | $2.08 | 257,248 | 536,311 | 257,247 | Nov 17, 2022, 04:56 PM |
Mor George Adi | Chief Scientific Officer | Nov 16, 2022 | Sale | $2.08 | 324,775 | 677,091 | 324,775 | Nov 17, 2022, 04:56 PM |
Marvin Donald | Executive VP, CFO & COO | Mar 16, 2022 | Buy | $3.27 | 500 | 1,637 | 2,000 | Jun 21, 2022, 06:01 AM |
Maryles Joel Michael | Director | May 24, 2022 | Buy | $2.88 | 433 | 1,247 | 1,433 | May 25, 2022, 04:03 PM |
Cohen Neil Harris | Director | May 18, 2022 | Buy | $3.19 | 2,000 | 6,380 | 12,409 | May 19, 2022, 04:02 PM |
Maryles Joel Michael | Director | Mar 18, 2022 | Buy | $4.34 | 1,000 | 4,340 | 1,000 | Mar 21, 2022, 06:04 AM |
Marvin Donald | Executive VP, CFO & COO | Mar 14, 2022 | Buy | $4.04 | 1,250 | 5,045 | 1,500 | Mar 21, 2022, 06:02 AM |
Pfost Dale R | Chief Executive Officer | Mar 14, 2022 | Buy | $3.98 | 2,500 | 9,943 | 2,500 | Mar 15, 2022, 04:10 PM |
Cohen Neil Harris | Director | Mar 14, 2022 | Buy | $4.35 | 6,000 | 26,120 | 10,409 | Mar 15, 2022, 04:07 PM |
Darvish Nissim | Director | Mar 11, 2022 | Buy | $4.28 | 1,200 | 5,136 | 1,200 | Mar 14, 2022, 04:20 PM |
Cohen Neil Harris | Director | Dec 06, 2021 | Buy | $7.43 | 2,000 | 14,860 | 4,409 | Dec 08, 2021, 07:29 AM |
Cohen Neil Harris | Director | Mar 16, 2021 | Buy | $41.51 | 2,409 | 99,998 | 2,409 | Mar 26, 2021, 10:27 AM |
OrbiMed Israel GP Ltd. | 10% Owner | Mar 16, 2021 | Option Exercise | $17.35 | 288,170 | 4,999,750 | 2,578,174 | Mar 18, 2021, 09:59 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
Owner | Relationship | Date | Value($) |
OrbiMed Israel GP Ltd. | 10% Owner | 01/03/2023 | 1,207,759 |
Mor George Adi | Chief Scientific Officer | 01/03/2023 | 30,663 |
Mor George Adi | Chief Scientific Officer | 01/03/2023 | 38,706 |
Cohen Neil Harris | Director | 11/16/2022 | 4,818 |
Mor George Adi | Chief Scientific Officer | 11/16/2022 | 536,311 |
Mor George Adi | Chief Scientific Officer | 11/16/2022 | 677,091 |
Marvin Donald | Executive VP, CFO & COO | 03/16/2022 | 1,637 |
Maryles Joel Michael | Director | 05/24/2022 | 1,247 |
Cohen Neil Harris | Director | 05/18/2022 | 6,380 |
Maryles Joel Michael | Director | 03/18/2022 | 4,340 |
Marvin Donald | Executive VP, CFO & COO | 03/14/2022 | 5,045 |
Pfost Dale R | Chief Executive Officer | 03/14/2022 | 9,943 |
Cohen Neil Harris | Director | 03/14/2022 | 26,120 |
Darvish Nissim | Director | 03/11/2022 | 5,136 |
Cohen Neil Harris | Director | 12/06/2021 | 14,860 |
Cohen Neil Harris | Director | 03/16/2021 | 99,998 |
OrbiMed Israel GP Ltd. | 10% Owner | 03/16/2021 | 4,999,750 |
Load More Insider Transactions
FUNDS WITH A POSITION IN CHEMOMAB THERAPEUTICS LTD
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
ORBIMED ADVISORS LLC | 2,241,274 | 0.02% | No change | Other |
GEODE CAPITAL MANAGEMENT, LLC | 11,737 | 0% | No change | Other |
CHANGE IN SHARES OUTSTANDING FOR CHEMOMAB THERAPEUTICS LTD
STOCK BUYBACKS FOR CHEMOMAB THERAPEUTICS LTD
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
10.08%
1Q
06/30/2023
17.41%
2Q
03/31/2023
17.77%
3Q
12/31/2022
15.52%
4Q
09/30/2022
13.77%
5Q
06/30/2022
14.07%
6Q
03/31/2022
14.11%
7Q
12/31/2021
6.67%
8Q
09/30/2021
14.18%
9Q
06/30/2021
20.35%
10Q
03/31/2021
66.04%
11Q
12/31/2020
80.82%
12Q
09/30/2020
86.71%
13Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR CHEMOMAB THERAPEUTICS LTD
LOADING...